Everand Logo

Welcome to Everand!

  • Discover millions of ebooks, audiobooks, and so much more with a free trial

    From $11.99/month after trial. Cancel anytime.

    Fast Facts: Treatment-Free Remission in Chronic Myeloid Leukemia: From concept to practice and beyond
    Fast Facts: Treatment-Free Remission in Chronic Myeloid Leukemia: From concept to practice and beyond
    Fast Facts: Treatment-Free Remission in Chronic Myeloid Leukemia: From concept to practice and beyond
    Ebook81 pages38 minutes

    Fast Facts: Treatment-Free Remission in Chronic Myeloid Leukemia: From concept to practice and beyond

    By S. Potluri

    ()

    Read preview

    About this ebook

    The tyrosine kinase inhibitor (TKI) imatinib was the first treatment to specifically target cancer cells, rather than the relatively indiscriminate effects of conventional chemotherapy on any rapidly dividing cells. This concept of targeted treatment in cancer is one of the important advances in modern medicine in the last 30 years. Indeed, treatment with TKIs has transformed chronic myeloid leukemia (CML) from a cancer with a poor prognosis to one in which many patients can expect a normal lifespan. Success with the TKIs has prompted the question of whether it is desirable – or feasible – for patients to remain on treatment for long periods. While the TKIs are targeted, they are associated with considerable toxicity, and long-term treatment has important economic implications for health services and patients. Thus, the concept of treatment-free remission (TFR) has emerged for patients in deep clinical remission. Clinical research over the last decade has focused on whether treatment can be stopped, how to best monitor patients while off treatment, and how to intervene before a clinical relapse. As this research progresses, the tantalizing prospect of a cure for some patients seems increasingly feasible. This new Fast Facts title outlines this trail-blazing approach to the long-term management of patients living with CML in remission. It explains the concepts of molecular and hematologic relapse, the highly sensitive technologies that allow disease monitoring, and how TFR is best managed in practice. It is a concise educational resource, ideal for any healthcare professional involved in the treatment of patients with CML who wants to understand TFR, particularly clinical nurse specialists and pharmacists who increasingly help clinicians to run CML clinics. Table of Contents: • The concept of treatment-free remission • Measurement of disease burden • Clinical practice • Future directions
    LanguageEnglish
    PublisherS. Karger
    Release dateJan 26, 2021
    ISBN9783318068344
    Fast Facts: Treatment-Free Remission in Chronic Myeloid Leukemia: From concept to practice and beyond

    Related to Fast Facts

    Related ebooks

    Medical For You

    View More
    View More

    Related podcast episodes

    Related articles

    • UNLIMITED

      Beating Cancer

      Feb 1, 2019

      Is cancer still a death sentence? No. Most cancers are preventable and also treatable. Cancer diagnosis and treatment have grown by leaps and bounds. We know the cause of at least 70 per cent of cancers now, around 60 per cent of cancers are now prev

      4 min read

    • UNLIMITED

      THE renaissance OF CELL THERAPIES

      Jul 28, 2019

      DR MARKUS DEPFENHART, PLASTIC AND AESTHETIC SURGEN In the late 1990s and early 2000s, there was huge hype around stem cells and their apparently almost unlimited potential, but unfortunately the expectations didn’t materialise. However, new scientifi

      2 min read

    • UNLIMITED

      What Defines a Stem Cell?

      Dec 27, 2018

      For the past three years, researchers at the Hubrecht Institute in the Netherlands have been painstakingly cataloging and mapping all the proliferating cells found in mouse hearts, looking for cardiac stem cells. The elusive cells should theoreticall

      5 min read

    • UNLIMITED

      These Compounds Starve Blood Cancer To Death

      Jan 2, 2018

      Newly synthesized compounds can starve multiple myeloma—a rare form of blood cancer—to death, according to a series of studies using patient samples. The new compounds offer “a new strategy for attacking multiple myeloma…” Tumor cells, including thos

      2 min read

    • UNLIMITED

      No More Chemo For Certain Types Of Breast Cancer

      Jul 2, 2018

      PHYLLIS LACETTI FOUND HER OWN BREAST CANCER WHEN she felt an abnormal lump in her right breast in 2007. A nurse at Montefiore Medical Center, she had a lumpectomy to remove it, but an MRI afterward revealed remaining cancer cells, so she opted to get

      5 min read

    • UNLIMITED

      ‘It’s Just Bad Care’: Many Breast Cancer Patients Receive More Radiation Than Needed

      Oct 23, 2017

      Only 48 percent of eligible breast cancer patients today get the shorter regimen, in spite of the additional costs and inconvenience of the longer type, an analysis shows.

      7 min read

    • UNLIMITED

      Death struggle

      Oct 31, 2021

      Death struggle
      8 min read

    • UNLIMITED

      Opinion: I’m A Doctor With End-stage Cancer. I Support Medical Aid In Dying

      Jan 31, 2018

      When my suffering from stage 4 prostate cancer becomes unbearable, I hope to have the option of medical aid in dying.

      4 min read

    • UNLIMITED

      Life Under Siege

      Dec 5, 2021

      Life Under Siege
      4 min read

    • UNLIMITED

      Nurse Practitioners Can Do More Than You Might Think

      Oct 17, 2018

      Adults in the United States have a limited understanding of the basic duties that nurse practitioners and physician assistants can perform, according to a new study. “Odds are, if you are a new patient and have been to ‘the doctor’s office’ recently

      1 min read

    • UNLIMITED

      Lauren Underwood’s Long Game

      Jul 17, 2021

      Lauren Underwood’s Long Game
      17 min read

    • UNLIMITED

      Opinion: Testing Medical Students Is Big Business. I See It As Extortion

      Mar 20, 2020

      As medical students plod along in the physician-trainee pipeline, it's easy for us to feel helpless in the face of community-sanctioned extortion by the National Board of Medical Examiners.

      3 min read

    • UNLIMITED

      The Best Integrative Cancer Specialists

      Nov 21, 2021

      The Best Integrative Cancer Specialists
      5 min read

    • UNLIMITED

      Treating The Untreatable Cancers

      Jul 26, 2020

      Treating The Untreatable Cancers
      4 min read

    • UNLIMITED

      Healing The Whole Person

      Jul 24, 2022

      The UK National Health Service reports that one in two people in the UK will develop cancer at some time in their lives. This is a stark and rather frightening statistic, not only because cancer is a leading cause of death but also because the usual

      7 min read

    • UNLIMITED

      Life Force

      Sep 1, 2022

      Life Force
      6 min read

    • UNLIMITED

      Detecting Cancer At The Earliest Stages

      Jul 24, 2022

      Detecting Cancer At The Earliest Stages
      7 min read

    • UNLIMITED

      Biotech Giant stumbles

      Dec 6, 2023

      Biotech Giant stumbles
      4 min read

    • UNLIMITED

      Weight-loss Drug Could Fight Resistant Lung Cancer

      Aug 5, 2018

      New research could pave the way for using versions of an existing drug to keep lung cancer cells from becoming drug-resistant. Researchers have discovered that a key enzyme in lipid metabolism controls the response to a class of targeted drugs called

      2 min read

    • UNLIMITED

      Testing And Monitoring

      Sep 24, 2023

      If you suspect skin cancer—or any cancer, for that matter—rest assured you have options regarding screening tools and diagnostic tests. Several specialized blood tests are extremely effective when it comes to early cancer detection. Though they are u

      1 min read

    Related categories

    Reviews for Fast Facts

    0 ratings

    0 ratings0 reviews

    What did you think?

    Tap to rate

    Review must be at least 10 words

      Book preview

      Fast Facts - S. Potluri

      Introduction

      The tyrosine kinase inhibitor (TKI) imatinib was the first treatment to specifically target cancer cells, rather than the relatively indiscriminate effects of conventional chemotherapy on any rapidly dividing cells. This concept of targeted treatment in cancer is one of the important advances in modern medicine in the last 30 years. Indeed, treatment with TKIs has transformed chronic myeloid leukemia (CML) from a cancer with a poor prognosis to one in which many patients can expect a normal lifespan.

      Success with the TKIs has prompted the question of whether it is desirable – or feasible – for patients to remain on treatment for long periods. While the TKIs are targeted, they are associated with considerable toxicity, and long-term treatment has important economic implications for health services and patients. Thus, the concept of treatment-free remission (TFR) has emerged for patients in deep clinical remission. Clinical research over the last decade has focused on whether treatment can be stopped, how to best monitor patients while off treatment, and how to intervene before a clinical relapse. As this research progresses, the tantalizing prospect of a cure for some patients seems increasingly feasible.

      This new Fast Facts title outlines this trail-blazing approach to the long-term management of patients living with CML in remission. It explains the concepts of molecular and hematologic relapse, the highly sensitive technologies that allow disease monitoring, and how TFR is best managed in practice.

      It is a concise educational resource, ideal for any healthcare professional involved in the treatment of patients with CML who wants to understand TFR, particularly clinical nurse specialists and pharmacists who increasingly help clinicians to run CML clinics.

      Chronic myeloid leukemia

      Chronic myeloid leukemia (CML) affects white blood cells in the myeloid lineage. About 780 new cases of CML are diagnosed in the UK each year.¹ CML used to have a poor prognosis, with a 5-year relative survival of 19–74% in Europe.²,³ However, it is now considered to be a model disease in which targeted therapies are giving many patients the possibility of long-term remission and a normal life span.

      The Philadelphia chromosome. In 1960, an abnormal chromosome was identified in bone marrow-derived white blood cells from patients with CML – the Philadelphia chromosome.⁴ Further research revealed that parts of the long arms of chromosomes 9 and 22 are exchanged⁵ – termed the t(9;22) translocation (Figure 1.1).

      Figure 1.1 The t(9;22) translocation produces the BCR–ABL1 fusion gene.

      BCR–ABL1 translocation. The t(9:22) translocation results in fusion of the genes for the breakpoint cluster region (BCR) and ABL proto-oncogene 1 (ABL1), creating the BCR–ABL1 fusion gene.

      ABL1 codes for a tyrosine kinase which, when phosphorylated, recruits other proteins involved in cell signaling. The fusion with BCR prevents the shuttling of ABL1 between the nucleus and cytoplasm so it stays in the cytoplasm where it can continuously recruit signaling proteins.

      BCR contains a coiled–coiled domain that allows two BCR–ABL1 proteins to join (dimerization) (Figure 1.2). This allows the ABL1 kinase domain (the active domain) to phosphorylate itself, promoting the further recruitment of signaling proteins and the activation of signaling pathways such as mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K) and

      Enjoying the preview?
      Page 1 of 1